Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ET-01 in Transfusion Dependent Beta-Thalassaemia
NCT04925206Phase 1Terminated
- Sponsor
- EdiGene Inc.
- Start
- Aug 2021
- Primary completion
- Jan 2024
- Modality
- CRISPR-Cas9, Gene Silencing, Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ET-01 in beta thalassemia, sponsored by EdiGene Inc. Primary endpoints: Frequency and severity of collected AEs & SAEs at 24 months, All-cause mortality at 24 months and 3 more. Started Aug 2021; status: terminated.
02
Drugs
ET-01
03
Conditions
beta thalassemia
Beyond the preview
Go deeper on NCT04925206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04925206.